About Biofrontera Inc.
https://www.biofrontera-us.comBiofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
CEO
Hermann Luebbert
Compensation Summary
(Year 2023)
Salary $470,500
Bonus $258,846
All Other Compensation $3,879
Total Compensation $733,225
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Went public October 29, 2021
Method of going public IPO
Full time employees 92
Ratings Snapshot
Rating : C
Discounted Cash Flow 1
Return On Equity 5
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Market Cap $699388
52w High $0.10
52w Low $0.06
P/E -0.05
Volume 7.80K
Outstanding Shares 11.66M
About Biofrontera Inc.
https://www.biofrontera-us.comBiofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $6.99M ▼ | $11.34M ▼ | $-6.65M ▼ | -95.15% ▼ | $-0.62 ▼ | $-6.33M ▼ |
| Q2-2025 | $9.03M ▲ | $11.73M ▲ | $-5.32M ▼ | -58.96% ▼ | $-0.57 ▲ | $-4.97M ▼ |
| Q1-2025 | $8.59M ▼ | $10.06M ▲ | $-4.2M ▼ | -48.94% ▼ | $-0.76 ▼ | $-3.87M ▼ |
| Q4-2024 | $12.56M ▲ | $9M ▼ | $-1.4M ▲ | -11.12% ▲ | $2.97 ▲ | $-1.12M ▲ |
| Q3-2024 | $9.01M | $9.1M | $-5.67M | -62.91% | $-0.98 | $-5.34M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $3.42M ▼ | $15.41M ▼ | $18M ▼ | $-2.58M ▲ |
| Q2-2025 | $7.25M ▲ | $20.14M ▲ | $24.81M ▲ | $-4.67M ▼ |
| Q1-2025 | $1.79M ▼ | $16.59M ▼ | $16.12M ▼ | $469K ▼ |
| Q4-2024 | $5.91M ▲ | $22.1M ▲ | $17.67M ▲ | $4.43M ▼ |
| Q3-2024 | $2.88M | $18.52M | $12.99M | $5.53M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-6.65M ▼ | $-3.82M ▼ | $1K ▲ | $0 ▼ | $-3.82M ▼ | $-3.82M ▼ |
| Q2-2025 | $-5.32M ▼ | $-3.04M ▲ | $-1K ▲ | $8.5M ▲ | $5.45M ▲ | $-3.05M ▲ |
| Q1-2025 | $-4.2M ▼ | $-4.12M ▼ | $-3K ▼ | $0 ▼ | $-4.12M ▼ | $-4.12M ▼ |
| Q4-2024 | $-1.4M ▲ | $-1.02M ▲ | $-1K ▼ | $4.05M ▲ | $3.03M ▲ | $-1.02M ▲ |
| Q3-2024 | $-5.67M | $-1.21M | $0 | $-298K | $-1.51M | $-1.21M |
Revenue by Products
| Product | Q4-2023 | Q3-2024 | Q2-2024 | Q1-2024 |
|---|---|---|---|---|
 Government and Payor Rebates | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Prompt Pay Discounts | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Returns | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Copay Assistance Program | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Hermann Luebbert
Compensation Summary
(Year 2023)
Salary $470,500
Bonus $258,846
All Other Compensation $3,879
Total Compensation $733,225
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Went public October 29, 2021
Method of going public IPO
Full time employees 92
Ratings Snapshot
Rating : C
Discounted Cash Flow 1
Return On Equity 5
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0